PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy Clinical Trials in Madrid

1 recruitingMadrid, Spain

Filters

Status

RecruitingNot yet recruitingEnrolling by invitationActive, not recruiting

Sex

MaleFemale

Your Age

Shows trials you qualify for by age

Phase

Phase 1Phase 2Phase 3Phase 4Early Phase 1Not Applicable

Study Type

InterventionalObservational

Country

United StatesCanadaUnited KingdomAustraliaGermanyFranceSpainItaly

Other Locations

Melbourne, Victoria1
El Paso, Texas1
Sapporo, Hokkaido1
Murdoch, Western Australia1
Malvern, Victoria1
Granada, Andalusia1

Showing 1–1 of 1 trials

Recruiting

Phase 1Phase 2

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

Novartis Pharmaceuticals123 enrolled11 locationsNCT07226986

ClinicalTrialsFinder

Helping patients and researchers find recruiting clinical trials. Updated regularly from ClinicalTrials.gov and ANZCTR.

Browse

Browse Conditions
Browse Drugs
Browse Locations
Browse Institutions
Search Trials
Get Trial Alerts

Resources

Clinical Trial Guides
FAQ
About Us
Contact
Partnerships
ClinicalTrials.gov
ANZCTR

Data Source

Trial data sourced from ClinicalTrials.gov and ANZCTR (Australian New Zealand Clinical Trials Registry)

Updated regularly to reflect the latest trial information

Medical Disclaimer: This site is for informational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before making decisions about participating in a clinical trial. Trial information may change; verify details directly with the trial sponsor or at the relevant registry (ClinicalTrials.gov or ANZCTR).

Data provided by ClinicalTrials.gov & ANZCTR